Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Gliomas
Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Gliomas
Recruiting · NCT05804227 · Registry updated 2026-06-12Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Gliomas | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, epithelial neoplasm, glioma, neoplasm, neuroepithelial neoplasm, primitive neuroectodermal tumor | Recruiting | Early phase 1 | 2026-06-12 | NCT05804227 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| BioMed Valley Discoveries, Inc | 6 |
| M.D. Anderson Cancer Center | 1145 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| M D Anderson Cancer Center | Houston | United States | 667 |